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Abstract: Eight streptophenazines (A–H) have been identified so far as products of 
Streptomyces strain HB202, which was isolated from the sponge Halichondria panicea 
from the Baltic Sea. The variation of bioactivities based on small structural changes 
initiated further studies on new derivatives. Three new streptophenazines (I–K) were 
identified after fermentation in the present study. In addition, revised molecular structures 
of streptophenazines C, D, F and H are proposed. Streptophenazines G and K exhibited 
moderate antibacterial activity against the facultative pathogenic bacterium Staphylococcus 
epidermidis and against Bacillus subtilis. All tested compounds (streptophenazines G, I–K) 
also showed moderate activities against PDE 4B. 
Keywords: marine natural product; phenazine; Baltic Sea; Streptomyces;  
Halichondria panicea; HPLC-DAD/MS; fermentation; PDE 4; antibiotic 
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1. Introduction 
Phenazines consist of two benzene rings linked through two nitrogen atoms and have been isolated 
as secondary metabolites of bacteria (Figure 1). Pyocyanin is the first natural phenazine discovered.  
It was found in the 1860s [1], when French clinicians observed blue colorations of pus-filled wounds 
of infected patients [2]. In 1882, Carle Gessard recognized bacteria as the producing organisms, which 
were named Bacillus pyocyaneus and are now known as Pseudomonas aeruginosa [1,2]. More  
than 6000 phenazines have been identified so far [3], with less than 170 of biological origin [4].  
The larger part of phenazines from biological origin was isolated from terrestrial microorganisms, only 
a small number originates from marine habitats. 
Figure 1. Core structure of phenazines.  
 
Due to the numerous possibilities of derivatization at the heteroaromatic chromophore, phenazines 
feature a large pool of structural diversity which covers a wide range of pharmaceutically relevant 
bioactivities with antibacterial, antifungal, antiviral and cytotoxic activities [3]. Minor differences in 
structure can have major effects on biological activity. The riminophenazine Clofazimine is a 
prominent example. It is used for the treatment of leprosy and was found to be potential for the 
treatment of drug-susceptible and drug-resistant M. tuberculosis strains [5]. Current studies of  
Liu et al. showed that the tricyclic phenazine skeleton is necessary for the activity against  
M. tuberculosis. Through replacement of the two phenyl groups at position C-2 and N-5, 
physicochemical properties as well as anti-tuberculosis potency could be enhanced [6]. 
This highlights the attractiveness to search for new phenazines and their derivatives and to analyze 
these in respect to their biological activities. Derivatives may be obtained by organic synthesis or by 
screening of biological phenazine producers. Among bacteria, a large number of phenazine derivatives 
can be found in a single strain indicating great efficiency of biological production. In former studies, 
this was shown for the marine Streptomyces strain HB202 aside from cultivation-based approaches 
also by genetic analysis [7,8]. Via detection of gene fragments phzE [7] and phzF [9], it was demonstrated 
that streptophenazines in this strain are produced by the regular phenazine biosynthesis pathway [1]. 
Eight derivatives of a new phenazine subgroup, the streptophenazines A–H, were isolated from 
cultures of this Streptomyces HB202 [10]. In part, the structures were revised later [11,12]. These 
streptophenazines have minor structural differences at positions C-1 and CH-2′, but exhibit important 
differences in their bioactivities. They are active against the Gram-positive bacteria Bacillus subtilis 
and Staphylococcus lentus. 
Preliminary analysis of cultures from fermentation of Streptomyces sp. HB202 indicated the 
presence of a much larger number of derivatives as described before, exhibiting different physicochemical 
properties. Here, we characterize three new derivatives of the streptophenazines with respect to chemical 
structure and bioactivity. We also discuss the structural diversity gained by biotechnological approaches.  
N
N
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2. Results and Discussion 
2.1. Metabolite Spectrum of HB202 
Structures of eight streptophenazines, produced by Streptomyces strain HB202, were described 
previously [10–12]. Figure 2 demonstrates the presence of almost 20 phenazines in extracts of this 
strain after fermentation in GYM4 medium. They have at least small differences in polarity resulting in 
different retention times after separation on a non-polar C18 phase. Though some of these compounds 
are produced in decent quantities, others are present only in minor amounts in the extracts. 
Figure 2. UV chromatogram of an extract of Streptomyces strain HB202 (at 250 nm)  
after fermentation in GYM4 medium for three days and extraction with EtOAc. For 
analysis, a RP-C18 column was used applying an H2O/CH3CN gradient on a VWR  
Hitachi Elite LaChrom system. Peak detection was done by DAD/MS. Numbers indicate 
identified streptophenazines. 1, 2, 3: new streptophenazines (I–K), 4: streptophenazine A, 
5: streptophenazine B, 6: streptophenazine C, 7: streptophenazine D, 8: streptophenazine F, 
9: streptophenazine G, 10: streptophenazine H, *: unknown streptophenazines  
(>10 different molecules). 
 
2.2. Structural Constitution of Streptophenazines 
2.2.1. Isolation and Structure of New Streptophenazines  
The oily brown extract obtained from combined cultures was analyzed via HPLC-DAD/MS.  
Due to the characteristic UV maxima and the differences in polarity of the derivatives, phenazines are 
easily identified in the chromatogram and can be separated into pure compounds using a preparative 
HPLC-UV system. The structure elucidation of the three compounds was based on the interpretation  
of different NMR spectra (
1
H, 
13
C, DEPT, 
1
H–13C HSQC, 1H–13C HMBC, 1H–1H COSY) and  
HRESI-MS analysis.  
3,4,5 
6 
8,9 
1 2 10 
* 
* 
* 
* 
7 
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Regarding the 
1
H-NMR spectra of the new compounds, it was obvious that all signals of protons 
belonging to the phenazine skeleton were identical. Significant differences could only be observed 
between the carbomethoxyl group and the carboxyl function at position C-1, as well as in the alkyl 
chain located at position CH-2′. Structures are shown in Figure 3. 
Figure 3. Structures of streptophenazines I–K (1–3). 
 
Streptophenazine I (1) was isolated as a yellow solid. The characteristic UV spectrum (λmax 215, 
251, 347 (sh), 360 (sh), 366) in addition to the chemical shifts of the four quaternary carbons (δ 144.7, 
142.9, 142.8, 141.9) adjacent to the two nitrogen atoms and the existence of aromatic hydrogen  
signals (δ 8.46–7.95) reasoned that 1 could be a phenazine. Through the alignment of NMR data 
(Table 1) with HRESI-MS analysis (m/z 455.21605 [M + H]
+
,
 
calcd for C25H31N2O6: 455.21766), a 
molecular formula of C25H31N2O6 was established. The spectroscopic data indicated either a 1,6- or a  
1,9-disubstituted phenazine skeleton. Due to this fact, data were compared to those of Yang et al. [11,12], 
who clearly defined the core structure of streptophenazines A, B, E and G to be 1,6-disubstituted via 
total synthesis as well as X-ray crystallographic data (streptophenazine A). Based on the high 
similarity of the NMR data in addition to the assumption of a common biosynthesic pathway of the 
derivatives in the same Streptomyces strain HB202, 1,6-disubstitution of new streptophenazines could 
be determined. The 1,6-disbubstitution was supplementary demonstrated by the use of NOESY spectra 
in the studies of Mitova et al. [10]. A singlet and the chemical hydrogen shift of 1-COOCH3 (δ 4.08), 
the corresponding carbon signal of the methyl group (δ 53.3) as well as the adjacent carbonyl signal  
(δ 168.9) indicated the presence of a methyl ester. The position was based on the 1H–13C HMBC 
coupling of the aromatic proton H-2 (δ 8.29). Furthermore the 1H–13C HMBC experiments revealed 
the occurrence of a second residue to be linked to the phenazine skeleton, an oxymethine substituent 
which led to a lowfield shift of CH-1′ (δ 71.4). The 1H–1H COSY correlation pointed out the presence 
of an adjacent methine proton (H-2′) whose carbon was bearing a carbomethoxy group. The 
comparison of 
1
H–13C HMBC with the DEPT spectrum led to the following methylene protons  
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H-3′-H-6′ as well as the oxymethine substituent (CH-7′) which terminated the alkyl chain in addition to 
the two methyl residues CH3-8′ and 7′-CH3.  
Table 1. NMR spectroscopic data of 1. 
Position δC, DEPT δH, J [Hz] COSY HMBC 
1 132.8, C    
2 133.6, CH 8.29 dd (6.9, 1.4) 3 1-COOCH3, 10a, 4  
3 130.9, CH 7.96 m 2, 4 4a, 1 
4 134.8, CH 8.46 dd (8.8, 1.4) 3 10a, 2 
4a 144.7, C    
5a 142.9, C    
6 143.2, C    
7 130.2, CH 8.03 m 8 1′, 5a, 9 
8 132.5, CH 7.99 m 7, 9 6 
9 130.4, CH 8.26 dd (8.6, 1.5) 8 7, 5a 
9a 142.8, C    
10a 141.9, C    
1′ 71.4, CH 6.16 d (7.7) 2′ 2′-COOCH3, 5a, 7 
2′ 55.0, CH 3.27 ddd (10.1, 7.7, 4.3) 1′  
3′ 30.5, CH2 
1.26 m,  
1.74 m 
  
4′ 25.2, CH2 1.17 m   
5′ 29.2, CH2 1.17 m   
6′ 44.6, CH2 1.24 m  4′ 
7′ 71.3, C    
8′ 29.2, CH3 1.03 s  5′, 6′ 
7′-CH3 29.2, CH3 1.03 s  5′, 6′ 
1-COOCH3 168.9, C    
1-COOCH3 53.3, CH3 4.08 s  1-COOCH3 
2′-COOCH3 176.8, C    
2′-COOCH3 52.1, CH3 3.63 s  2′-COOCH3 
The structure of 1 was quite similar to that of streptophenazine H (10) with the only difference of 
one missing methylene at 10, resulting in a molecular weight with 14 mass units less. The structure  
of 1 is shown in Figure 3, as well as in Figure 4 illustrated through arrows of 
1
H–13C HMBC 
correlations. Spectroscopic data are shown in Table 1. 
Streptophenazine J (2) is an isomer of 1 comparing the molecular formula C25H31N2O6, established 
via HRESI-MS (m/z 455.21637 [M + H]
+
, calcd for C25H31N2O6: 455.21766), the UV spectrum and  
the NMR signals of the skeleton. Analysis of 
1
H–1H COSY data showed that one of the methyl groups  
(7′-CH3 of 1) is missing. Instead, a 
1
H–1H COSY correlation of H-6′ pointed out the presence of 
another methyl group at CH-6′ in this molecule. Unfortunately, 2 is stereochemically unstable for 
which reason it is difficult to do an accurate structure elucidation. This information led to the structure 
of 2 as shown in Figure 3 with undefined absolute configuration.  
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Figure 4. Selected 
1
H–13C HMBC (arrows) and 1H–1H COSY (bold) correlations, relevant 
for structure elucidation of 1. 
 
Streptophenazine K (3) showed structural similarities to streptophenazine G (9) except an unesterified 
carboxyl group at position C-1. This was based on the highfield shift of C-1 (δ 126.6) as well as on the 
observations of the 
1
H-NMR spectrum similar to that of 9 with the appearance of only one methoxyl 
group (2′-COOMe) and a difference of 14 mass units. HRESI-MS pointed out the molecular formula 
C24H29N2O5 (m/z 425.20875 [M + H]
+
, calcd for C24H29N2O5: 425.20710). The structure of 3 is shown 
in Figure 3. 
The relative configurations of streptophenazines I-K 1–3 at C-1′ and C-2′ were determined using the 
3
J coupling constants between the protons at these carbon atoms. Yang et al. [11,12] found that the 
like-configuration (R,R or S,S) in the very similar streptophenazines A or G had a coupling constant of 
6.5 Hz, while the unlike-configuration (R,S or the S,R) had one of 7.5 Hz. The compounds 1, 2 and 3 
showed coupling constants of 7.7, 7.8 and 7.5 Hz, respectively, and thus should all have the  
unlike-configuration at C-1′ and C-2′.  
For assignment of the absolute configuration, CD measurements were performed of streptophenazines 
I and K, and of (–)-streptophenazine G 9 whose absolute configuration was known from total  
synthesis [12]. Despite the presence of a large chromophore, all compounds surprisingly gave CD 
curves of very low intensity (Figure 5). This was explained by the fact that structures of this type have 
pseudo-enantiomeric conformers, in which the stereocenters in the side chain are on different sides of 
the chromophore. These conformations lead to nearly mirror-image like single CD spectra, and thus in 
the overall CD curve the net rotational strengths nearly cancel out. However, it was possible to get 
reproducible spectra and we were able to elucidate the absolute configurations of the compounds by 
comparing the experimental CD spectra of 1 and 3 with that of (–)-streptophenazine G 9. They have the 
same chromophore and the free carboxylic acid group of streptophenazine K will influence the CD 
curve in comparison to the ester group of streptophenazines I and G only marginable. Of course, the 
comparison of the CD spectra can only give the absolute configuration of C-1′ (that of C-2′ is then 
deduced from the coupling constants as described above). All other stereocenters (C-6′ in  
(–)-streptophenazine G and in streptophenazine K) are too far away from the chromophore to have an 
impact on the electronic CD. Finally, the nearly identical CD spectra of streptophenazines I and K with 
N
N
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7
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that of (–)-streptophenazine G proved that they were all 1′S,2′R-configured as shown in Figure 3. 
Unfortunately, it was not possible to measure a reproducible CD spectrum of streptophenazine J 2, 
most probably due to the generally low intensity of CD curves of the spreptophenazines in combination 
with the fact that it was stereochemically not stable. 
Figure 5. Comparison of the CD spectra of (–)-streptophenazine G, streptophenazine I, and 
streptophenazine K. 
 
2.2.2. Structure Revision of Streptophenazines B–F and H and Structural Comparison 
The structures of streptophenazines A (4), B (5), E (11) and G 9 have recently been revised [11,12]. 
The revision of 5 and 11 is shown in the supplement of Yang et al. [11]. Due to new interpretations of 
NMR spectra, which indicate that current structures of these derivatives are not correct [10], a revision 
is also needed for the streptophenazines C (6), D (7), F (8) and H 10.  
The result of the new investigation was, that the published structures of Mitova et al. [10] are 
incorrect, and consequential the residues at CH-1′ and CH-2′ have to be switched. This was shown by 
the 
1
H–13C HMBC correlation of H-7 to CH-1′ and in addition to that the lowfield shift of CH-1′ in the 
13
C and 
1
H spectra, which was caused by the adjacent hydroxyl group. The revised structures are 
shown in Figure 6.  
Figure 6. Revised structures of streptophenazines A–H [10–12]. 
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Figure 6. Cont. 
 
2.3. Bioactivity Assays  
Bioactivities of 1–3 were measured because of their novelty and compared with those of 9 as a 
known representative of streptophenazines. The results are shown in Table 2. 
Table 2. Bioactivities of compounds 1–3 and 9. 
 
Bacillus subtilis  
(IC50 [µM]) 
Staphylococcus epidermidis  
(IC50 [µM]) 
PDE 4B  
(IC50 [µM]) 
Streptophenazine G 9 8.2 µM (± 0.9) 8.4 µM (± 0.5) 5.2 (± 1.0) 
Streptophenazine I 1 not active not active
 
11. 6 (± 1.1) 
Streptophenazine J 2 not active not active 12.0 (± 0.9) 
Streptophenazine K 3 21.6 (± 6.8) 14.5 µM (± 2.0) 12.2 (± 2.0) 
Rolipram not determined not determined 0.75 (± 0.05) 
Streptophenazines A–H have been shown to be antibiotically active against the Gram-positive 
bacteria Bacillus subtilis and Staphylococcus lentus [10]. Because of its clinical relevance, Staphylococcus 
epidermidis was used as a test strain in this study in addition to Bacillus subtilis [13]. 3 and 9 inhibited 
the growth of Staphylococcus epidermidis with IC50 values of 14.5 µM and 8.4 µM, respectively.  
Both 3 and 9 were also active against Bacillus subtilis with IC50 values of 21.6 µM and 8.2 µM, 
respectively. No antibacterial activity was observed for the compounds 1 and 2. All four compounds 1–3 
and 9 showed inhibitory activity against the enzyme phosphodiesterase (PDE 4B). 
There is a great interest in the discovery of new drugs for the treatment of inflammatory diseases 
such as COPD. Since it was observed, that the function of inflammatory cells could be inhibited by an 
increase of 3′5′-cyclic adenosine monophosphate (cAMP), inhibitors of the phosphodiesterases (PDEs) 
were considered as promising drug candidates [14]. The increase in the cAMP results by the inhibition 
of hydrolyses of cAMP to the inactive 5′ monophosphate (5′-AMP). As a result, there is a reduction in 
the inflammatory cell activity, an inhibition of fibrosis and a relaxation of smooth muscles [14].  
The non-selective PDE inhibitor theophylline (since the 1930s) and the selective PDE4 inhibitor 
benzamide roflumilast-N-oxide, which has been approved by the FDA in 2011, are drugs for the 
treatment of COPD [15]. Roflumilast-N-oxide showed IC50 values in the range of 0.4 to 7.8 nM 
dependent on the used PDE4 isoenzyme [16]. Further PDE4 inhibitors, such as rolipram, cilomilast, 
oglemilast, tetomilast, ONO-6126, and ELB353 are in several stages of clinical trials. As far as known, 
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phenazines were not yet identified as PDE4 inhibitors. In this study, moderate activity against PDE4 
was observed for all four streptophenazines tested. 
2.4. Biotechnological Upscaling 
Lead structure development and entering of (pre-)clinical phases for newly identified natural 
products depend on sufficient supply of material. For this purpose, chemical synthesis and biotechnological 
production have to be considered and compared in terms of feasibility, effort and costs. When aiming 
for a variety of derivatives, biological production may have advantages, as it seems to be a common 
feature of many microbes to produce more than one derivate of a given compound. However, upscaling 
of the biotechnological production from in most cases Erlenmeyer flask cultures to controllable stirred 
tank reactors (STR) is a challenge, as the scaling itself is a change of cultivation conditions that may 
lead to a change of the secondary metabolite profile [17,18]. Especially in the case of HB202 being 
very sensitive to changes in the cultures, the scaling did bear many risks.  
Figure 7 illustrates the scaling process, which included optimization of cultivation conditions  
with the aim of enhancing production of the streptophenazines at each step. The original cultures that 
lead to the identification of the streptophenazines were done in Erlenmeyer (EM) flasks. EM flasks 
were used for cultivation in 1 L scale at different pH values, pH 9 turned out to be best for production 
of secondary metabolites by Streptomyces sp. HB202. For all subsequent experiments in STR, the pH 
value was set to constant pH 9 being a relatively harsh condition. Controlled STR cultures where done 
in 10 L and 200 L cultures. Figure 7 shows the process of production in the two fermenter systems.  
Figure 7. Fermentation of Streptomyces HB202 at 28 °C in GYM medium. Comparison of 
streptophenazine production in consideration of pO2 and pH within two different tank 
reactors using stable pH conditions at pH 9; (a) 10 L culture in a stirred tank reactor (STR) 
(b) 200 L culture in a STR; ● pO2 [%], ■ pH, ▲ production of streptophenazines I/J [IC]. 
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Figure 7. Cont.  
 
(b) 
Streptophenazine production occurred in the late exponential phase (as shown by the rising pO2).  
In the 10 L scale, the maximum yield was obtained after 90 h. The process time was decreased to 40 h 
by scaling to 200 L (maximum yield). Additionally, the maximum yield could further be increased 
within this step. A proceeding cultivation led to a decrease of streptophenazines. However, not only 
the streptophenazines I/J were found but a variety of further streptophenazine derivatives (minimum 
20 different derivatives).  
Exemplary, the yield was determined for the derivative pair streptophenazine I and J. The 
Erlenmeyer culture yielded 104 µg/L, the same order was obtained in the 10L STR (109 µg/L). The 
scaling to the 200 L culture doubled the yield to 196 µg/L.  
The scaling of the fermentation led to an increase in product yield and a significant reduction of 
process time, which was further reduced by an optimization of the capture step. The metabolites of 
HB202 were secreted into the culture medium as well as are stored in the cells. Hence, both had to be 
collected and processed subsequent to the fermentation. The standard method in small scale comprised 
solvent extraction with two volumes of EtOAc per liter of culture broth. To avoid the large amount of 
solvent necessary for the processing of 200 L of culture, a capture step was introduced. The scavenger 
XAD was used to adsorb small molecules from the broth (Figure 8). Downstream processing in marine 
biotechnology seems to be the neglected child of bioprocess engineering. The application of a 
scavenger is only the first step of optimization of the downstream process. To be able to valorize 
compounds from marine microorganisms, big efforts must be made in the downstream process [19]. 
Because of a production decline in the tank reactors at the end of fermentation and due to losses 
during the subsequent purification of the streptophenazines from the crude extract only 56%–57% of 
the compounds could be gained. 505.5 µg were purified in total from the 10 L STR (57% of the 
produced amount), 22.4 mg from the 200 L system (56%). The yields and losses may be compared to 
the yield of stereoselective synthesis, as shown by Yang et al. streptophenazine A (1′S,2′R) was 
synthesized with a yield of 60% in the last step (60 mg from 135 mg of the precursor methyl 6-((1S, 
2R)-2-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)-1-hydroxy-6-methylheptyl)phenazine-1-carboxylate). 
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Organic synthesis was shown to be relatively effective for some streptophenazine derivatives. In terms 
of production costs and time, this synthesis is quite promising. However, biotechnological production, 
as shown in our experiments, can be feasible as well: A stirred tank reactor production followed by a 
XAD capture step and subsequent HPLC based purification yields appr. 20 mg of product. The 
biotechnological approach gains a natural “derivatization”, up to 20 different streptophenazines may be 
produced by one process. A good understanding of the production process will provide ample 
opportunities for successful scale up to the industrial level. Discovery scientists can have an 
impression on the various options available for scale-up of their lead product. A recent study 
demonstrated that in many cases of marine biotechnology, a suboptimal production yield was gained as 
technological barriers were limiting the process [20]. A special challenge to bioengineers is e.g., 
provided by barophilic strains originating from depths of, say, nearly 11,000 m, or from hydrothermal 
vents [19]. However, in the case of HB202, a standard optimization process could be applied. 
Figure 8. Process of sample treatment after cultivation procedure; Separation into culture, 
supernatant and cell pellet and subsequent extraction with EtOAC and partition of cell 
components; Assembling of both extracts and purification using preparative HPLC.  
 
3. Experimental Section  
3.1. General Experimental Procedures 
The optical rotation was measured on a Perkin-Elmer model 241 polarimeter. 
NMR spectra were recorded on a Bruker DRX500 spectrometer (500 and 125 MHz for 
1
H and  
13
C NMR, respectively), using the signals of the residual solvent protons and the solvent carbons as 
internal references (δH 3.31 and δC 49.15 ppm for CH3OH-d4). High-resolution mass spectra were 
acquired on a benchtop time-of-flight spectrometer (MicrOTOF-II, Bruker Daltonics, Bremen, 
Germany) with positive electrospray ionization.  
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Analytical reversed phase HPLC-DAD/MS experiments were performed using a C18 column 
(Phenomenex Onyx Monolithic C18, 100 × 3.00 mm) applying an H2O (A)/CH3CN (B) gradient  
with 0.1% formic acid added to both solvents (gradient: 0 min 5% B, 4 min 60% B, 6 min 100% B;  
flow 2 mL/min) on a VWR Hitachi Elite LaChrom system (DAD-detector: Hitachi L-2450 diode array 
detector) coupled to an ESI-ion trap detector with positive ionization (Esquire 4000, Bruker Daltonics). 
Semi-preparative HPLC-DAD was carried out using a Phenomenex normal phase column (Luna 5U 
Silica (2), 100A, 250 × 10.00 mm, 5 micron). 
For preparative fractioning a HPLC-UV system (VWR International LaPrep, Pump P311, Detector 
P110, autosampler smartline 3900) with a RP-C18 column (Phenomenex Gemini C18, 110A, AXIA, 
100 × 50.00 mm) applying an H2O (A)/CH3CN (B) gradient with 0.1% formic acid (gradient: 0 min 
10% B, flow 40 mL/min; 0.5 min 10% B, 17.5 min 60% B, 22 min 100% B; flow 100 mL/min) was used. 
3.2. Isolation and Identification of Strain Streptomyces sp. HB202 
Strain HB202 was isolated from the marine breadcrumb sponge Halichondria panicea (class 
Demospongia) collected from the Baltic Sea (Germany) [8]. The taxonomic identification was based 
on morphological criteria such as the cream color, a compact-solid surface, a sheet with neat round 
pores (osculae) and anastomosing hollow branches with osculae at the tip [21]. Isolation and 
identification of strain HB202 was described by Mitova et al. [10]. The most closely related type 
strains according to the 16S rRNA gene sequence (GQ863918, 1473 bp) were Streptomyces 
tanashiensis IFO 12919
T
 (GenBank/EMBL/DDBJ acc. No. AY999856) and Streptomyces 
griseoplanus AS 4.1868
T
 (GenBank/EMBL/DDBJ acc. No. AY999894) with a sequence similarity of 
99.93% for both strains. Several type strains of Streptomyces species exhibited sequence similarities 
≥99.80%, such as Streptomyces badius NRRL B-2567 (GenBank/EMBL/DDBJ acc. no. AY999783), 
Streptomyces mediolani LMG 20093
T
 (GenBank/EMBL/DDBJ acc. No. AJ781354) and Streptomyces 
griseus ATCC 51928
T
 (GenBank/EMBL/DDBJ acc. No. AF112160). 
3.3. Cultivation, Extraction and Substance Characterization 
Streptomyces sp. HB202 was cultivated in 1 L Erlenmeyer flasks using different pH values. The 
cultivation was subsequently scaled up in stirred tank reactors in 10 L (Braun Biostat, glass tank, 
containing 8 L culture) and in 300 L scale (Infors Techfors 300, steel tank, containing 200 L culture) 
using pH 9 (controlled via addition of 3 M NaOH). 
Precultures were established from cryocultures in a standardized manner as the strain was very 
susceptible for changes and reacted with a dramatic change of the metabolite spectrum. Precultures 
were carried out on agar plates, which were incubated after inoculation using the Microbank system 
(MAST DIAGNOSTIKA, Reinfeld, Germany) and in liquid medium at 28 °C in the dark.  
In each case, the seed medium for the marine strain Streptomyces HB202 consisted of 4 g glucose,  
4 g yeast extract, 4 g malt extract per 1 L demineralized water. Cultivation in Erlenmeyer flasks was 
done for up to seven days in different starting pH values. While the 10 L fermenter was run for 159 h 
at 28 °C, the pilot scale fermenter was run for 69 h. In the STR systems, pH, oxygen, CO2-outlet and 
stirring speed were controlled. The oxygen content in the medium was set to a minimum of 30% air 
saturation. Foam formation was stopped by addition of antifoam (Sigma, Taufkirchen, Germany).  
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After cultivation, cells were separated from the culture broth by means of centrifugation. For  
the 1 L and 10 L scale, culture supernatant and cells were extracted by addition of 2 Volumes EtOAc. 
The organic solvent was separated and concentrated to dryness under reduced pressure. For the 200 L 
scale, cells (appr. 6 L cell pellet) were treated in the same manner as cells from smaller cultivations. 
The culture supernatant was supplemented with XAD16 (Amberlite, 5 g/L). The XAD was recovered 
and transferred to a glass column. Substances were washed out using MeOH. Both crude extracts were 
assembled and subjected to preparative HPLC-UV. The concentrated fractions were subsequently 
purified using semi-preparative HPLC-DAD. The structures of the substances were elucidated using 
NMR and UV/VIS spectra. 
Streptophenazine I 1: Yellow solid; 3.0 mg, [α]20 D  −21° (c 0.0475, MeOH); UV (MeOH) λmax 215, 
251, 347 (sh), 360 (sh), 366; for 1D and 2D NMR data (MeOH-d4, 500 MHz and 125 MHz, 
respectively) see Table 1; HRESIMS m/z 455.21605 [M + H]
+ 
(calcd for C25H31N2O6: 455.21766). 
Streptophenazine J 2: Yellow solid; 6.6 mg, [α]20 D  −18° (c 0.1125, MeOH); UV (MeOH) λmax 215, 
251, 348 (sh), 360 (sh), 366; 
1
H NMR (CH3OH-d4, 500 MHz) δH 8.45 (1H, m, H-4), 8.28 (1H, dd,  
J = 7.0, 1.4, H-2), 8.26 (1H, dd, J = 8.6, 1.5, H-9), 8.03 (1H, d, J = 6.9, H-7), 7.99 (1H, m, H-8), 7.95 
(1H, m, H-3), 6.17 (1H, d, J = 7.8, H-1′), 4.08 (3H, s, 1-COOCH3), 3.63 (3H, s, 2′-COOCH3), 3.44 
(1H, m, H-7′), 3.27 (1H, ddd, J = 10.3, 7.8, 4.4, H-2′), 1.73 (1H, m, H-3′a), 1.29 (m, 1H, H-5′a), 1.25 
(1H, m, H-3′b), 1.24 (2H, m, H-4′), 1.23 (1H, m, H-6′), 0.97 (3H, m, H-8′), 0.93 (1H, m, H-5′b), 0.73 
(3H, m, 6′-CH3); 
13
C NMR (CH3OH-d4, 500 MHz): δC 176.8 (C, 2′-COOCH3), 168.9 (C,  
1-COOCH3), 144.7 (C, C-6), 143.1 (C, C-5a), 142.9 (C, C-4a), 142.8 (C, C-9a), 141.8 (C, C-10a), 
134.8 (CH, C-4), 133.6 (CH, C-2), 132.7 (C, C-1), 132.5 (CH, C-8), 130.8 (CH, C-3), 130.5 (CH, C-9), 
130.2 (CH, C-7), 72.0 (CH, C-7′), 71.3 (CH, C-1′), 55.0 (CH, C-2′), 53.3 (CH3, 1-COOCH3), 52.1 
(CH3, 2′-COOCH3), 40.8 (CH, C-6′), 33.3 (CH2, C-5′), 30.8 (CH2, C-3′), 26.3 (CH2, C-4′), 20.2 (CH3, 
C-8′), 14.7 (CH3, 6′-CH3); HRESIMS m/z 455.21637 [M + H]
+ 
(calcd for C25H31N2O6: 455.21766). 
Streptophenazine K 3: Yellow solid; 10.0 mg, [α]20 D  −64° (c 0.0900, MeOH); UV (MeOH) λmax 216, 
252, 271 (sh), 361 (sh), 370; 
1
H NMR (CH3OH-d4, 500 MHz) δH 8.81 (1H, dd, J = 7.0, 1.4, H-2), 8.56 
(1H, dd, J = 8.7, 1.4, H-4), 8.26 (1H, dd, J = 7.9, 2.2, H-9), 8.11 (1H, m, H-7), 8.09 (1H, m, H-8), 8.08 
(1H, m, H-3), 6.18 (1H, d, J = 7.5, H-1′), 3.62 (3H, s, 2′-COOCH3), 3.25 (1H, ddd, J = 10.4, 7.5, 4.6, 
H-2′), 1.72 (1H, m, H-3′a), 1.30 (1H, m, H-7′a), 1.24 (2H, m, H-4′), 1.11-1.19 (3H, m, H-3′b, H-5′a,  
H-6′), 0.93-1.05 (2H, m, H-5′b, H-7′b), 0.75 (3H, m, 6′-CH3), 0.74 (3H, m, H-8′); 
13
C NMR  
(CH3OH-d4, 500 MHz): δC 176.6 (C, 2′-COOCH3), 168.5 (C, 1-COOH), 143.7 (C, C-6), 143.6 (C, C-4a), 
143.4 (C, C-5a), 141.6 (C, C-9a), 141.3 (C, C-10a), 138.1 (CH, C-2), 136.5 (CH, C-4), 134.4 (CH,  
C-8), 131.7 (CH, C-3), 130.6 (CH, C-7), 128.7 (CH, C-9), 126.6 (C, C-1), 70.9 (CH, C-1′), 54.9 (CH, 
C-2′), 52.1 (CH3, 2′-COOCH3), 37.4 (CH2, C-5′), 35.5 (CH, C-6′), 30.7 (CH2, C-3′), 30.4 (CH2,  
C-7′), 26.0 (CH2, C-4′), 19.5 (CH3, 6′-CH3), 11.8 (CH3, C-8′); HRESIMS m/z 425.20875 [M + H]
+ 
(calcd for C24H29N2O5: 425.20710). 
1
H NMR spectra, COSY spectra,
 13
C NMR spectra, DEPT spectra, HSQC spectra and HMBC 
spectra of compounds 1–3 are available as Supplementary Information. 
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3.4. Determination of Biological Activity 
The antimicrobial assay was performed using Staphylococcus epidermidis DSM 20044 and  
Bacillus subtilis DSM 347. Overnight cultures of the strains cultivated in tryptic soy broth were diluted 
to an OD (600 nm) of 0.01–0.05. The assays were prepared by transferring 2 µL of a 10 mM solution 
of the tested compound dissolved in DMSO into one well of a 96-well microtiter plate containing  
200 µL of cell suspension culture. After the incubation of the microtiter plates for 5 h at 37 °C, 10 µL 
of a resazurin solution (0.2 mg/mL phosphate-buffered saline) was added to each well and the plates 
were incubated again for 5–30 min. Cell viability was assessed by the reduction of resazurin to 
resorufin by measuring the absorbance 600 nm (reference 690 nm). The resulting values were 
compared with a positive control (10 mM chloramphenicol) and a negative control (no compound) on 
the same microtiter plate.  
The inhibitory activity of the enzyme phosphodiesterase type 4B was determined according to 
Schulz et al. [22]. 
4. Conclusions  
The chromatogram of the marine Streptomyces strain HB202 showed a number of peaks which 
indicate the appearance of a huge number of phenazines in one fermentation approach. Eight of these 
streptophenazines were described by Mitova et al. [10] and revised by Yang et al. (A, B, E [11],  
G [12]) and in this publication (C, D, F, H). The structure of three new streptophenazines was 
elucidated and their activity in selected bioassays tested in this work, revealing that all derivates 
showed moderate activities against PDE4B. Due to the fact that so far phenazines are not known as 
PDE inhibitors, these bioactivities indicate additional medical indications for the pharmaceutical use of 
phenazines. E.g. streptophenazines may be considered for the treatment of COPD.  
Streptophenazines occur with an amazing variety of derivatives in nature, in this case with more 
than 20 derivatives produced by a single marine Streptomyces strain. This “biological derivatization” 
allows structure-function relationship studies without extensive chemical synthesis approaches. In 
terms of enhancing production levels for biotechnological production of streptophenazines, we 
demonstrated production at the 200 L scale in stirred tank reactors, yielding 39.3 mg/L streptophenazine 
I and J with a subsequent capture step and purification of the compounds via preparative HPLC. 
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